A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma
immunohistochemistry staining method
+ biopsy
+ surgery
Adenocarcinoma+12
+ Bronchial Neoplasms
+ Carcinoma
Diagnostic Study
Summary
Study start date: July 1, 1999
Actual date on which the first participant was enrolled.OBJECTIVES: Determine the relationship between three indicators of occult metastases (cytological examination of pleural lavage, immunohistochemistry (IHC) assay of lymph nodes, and IHC assay of rib bone marrow) and survival of patients with resectable non-small cell lung cancer. Determine the relationship between these indicators and conventional histology. Model survival considering the indicators and other patient attributes that are of prime prognostic significance. Determine the relationships between the indicators and the site of first recurrence in these patients. Determine the prevalence of the indicators in these patients. Determine the relationships between the indicators and disease free survival in these patients.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.1310 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Patient must be ≥ 18 years old. Patient must have ECOG/Zubrod status < 3. Patient must have clinically resectable, NSCLC (squamous cell, adenocarcinoma, or large cell) and be clinical Stage I, IIa, IIb or IIIa, according to the 1998 staging system of the American Joint Commission on Cancer for lung cancer. Patient must have N1 or N2 disease. NOTE: Patient must undergo mediastinoscopy if preoperative studies suggest N3 disease. Patient must have a pathologic diagnosis (pre-operative or intra-operative) of NSCLC prior to registration. Patient must be anticipated to have a thoracotomy with the intention of a curative resection for primary NSCLC. NOTE: The preoperative assessment of resectability should, at a minimum, include a CT scan of the chest and upper abdomen, including the adrenal glands, within 60 days prior to registration. Patient must be medically fit for surgery. Patient must be a candidate for complete resection of the carcinoma via pneumonectomy, bilobectomy, lobectomy, or anatomic segmentectomy with or without sleeve resection. Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures. Patient must be available for follow-up. If the patient is a survivor of a prior cancer, all of the following criteria must apply: Patient has undergone potentially curative therapy for all prior malignancies, No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone), Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies. Exclusion Criteria: Patient has evidence of pleural effusion by physical assessment, lateral chest x-ray, or by chest CT scan. Patient has had ipsilateral thoracotomy or thoracoscopy within the past 5 years. Patient has received prior chemotherapy or radiotherapy for this cancer. Patient is considered a poor surgical risk due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options. Patient for whom the surgeon plans to perform only a wedge resection for treatment.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 58 locations
Mobile Infirmary Medical Center
Mobile, United StatesUSC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, United StatesHuntington Cancer Center at Huntington Hospital
Pasadena, United States